RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
Upper airway results rest on 14 attacks in seven participants.
Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.